PassFinals
Endocrinology & Metabolic

Metabolic syndrome

Metabolic syndrome is a high-risk clustering of central adiposity, dysglycaemia, raised blood pressure and atherogenic lipids; it is a risk marker rather than a separate disease, so management is formal cardiovascular-risk assessment plus targeted treatment of weight, glucose, lipids and blood pressure.

In a nutshell

Metabolic syndrome is a risk cluster, not a separate disease to prescribe for. Measure central adiposity, blood pressure, lipids and glucose, calculate overall cardiovascular risk, prevent or treat type 2 diabetes and support sustainable weight and activity change.

Classic presentation

An asymptomatic person with central adiposity, raised blood pressure, atherogenic lipids and HbA1c in the non-diabetic hyperglycaemia range found during a health check.

Key points

  • Insulin resistance and visceral adiposity link the phenotype.
  • There is no single metabolic-syndrome drug; treat each component to its own pathway.
  • Use QRISK3 and clinical modifiers rather than assuming the cluster itself gives a treatment threshold.
  • NICE PH38 supports intensive prevention for people at high risk of type 2 diabetes.
  • Look for MASLD, sleep apnoea, PCOS, CKD and secondary dyslipidaemia.

First-line investigation

BMI/central-adiposity assessment, accurate blood pressure, full lipid profile, HbA1c or fasting glucose and formal cardiovascular-risk assessment.

Management

Identify established disease

  • Check for diagnostic-range hyperglycaemia, severe blood pressure elevation, established CVD, CKD and severe hypertriglyceridaemia that require their own urgent pathways.3,4

Measure the risk profile

  • Measure central adiposity, blood pressure, full lipids, HbA1c/glucose and relevant renal/liver markers, then calculate QRISK3 where appropriate.3,1,2

Reduce weight and global risk

  • Offer sustained behavioural weight-management support and treat CVD risk factors according to NICE lipid, blood-pressure and diabetes pathways.1,3,4

Prevent diabetes

  • Offer intensive diabetes-prevention support for high-risk non-diabetic hyperglycaemia and arrange repeat assessment according to PH38.2

Refer complex obesity and comorbidity

  • Use specialist weight-management or bariatric pathways when criteria are met, and manage sleep apnoea, MASLD, PCOS, CKD or severe dyslipidaemia in the appropriate service.1,3,5

Review response

  • Recheck weight, blood pressure, glucose/HbA1c, lipids, adherence and treatment effects, and reassess cardiovascular and diabetes risk after lifestyle change.3,2,1

Exam traps

  • Do not treat the label as a diagnosis with a single drug.
  • Ethnicity and clinical context affect central-adiposity and diabetes-risk thresholds.
  • High triglycerides with severe abdominal pain is an acute pancreatitis-risk problem, not just a chronic risk marker.
  • Established diabetes, CVD or CKD overrides a simplistic syndrome definition and needs its own guideline pathway.

Illustrations

Acanthosis nigricans as a marker of insulin resistanceAxillary acanthosis nigricans with velvety hyperpigmented thickening and skin tags, a clinical marker associated with insulin resistance and obesity.Klaus D. Peter, Wikimedia Commons · CC-BY-3.0-DE

Key sources

  1. NICE NG246: Overweight and obesity management (Current NICE recommendations on central adiposity assessment, behavioural weight management, physical activity, weight-management medicines and bariatric referral; accessed 4 August 2026.)
  2. NICE PH38: Type 2 diabetes: prevention in people at high risk (NICE prevention pathway covering risk identification, non-diabetic hyperglycaemia, intensive lifestyle change and reassessment; published 12 July 2012 and last reviewed 28 March 2018; accessed 4 August 2026.)Updated 28 Mar 2018
  3. NICE NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification (Current NICE recommendations on QRISK3, lifestyle, lipid assessment, primary-prevention statin decisions, secondary dyslipidaemia and follow-up; published 14 December 2023 and last reviewed 2 September 2025; accessed 4 August 2026.)Updated 2 Sept 2025
  4. NICE NG28: Type 2 diabetes in adults: management (Current NICE recommendations for established type 2 diabetes glycaemic, cardiovascular, renal and weight-related management; current page accessed 4 August 2026.)
  5. British National Formulary (BNF) (Current UK prescribing information for atorvastatin, antihypertensives and weight-management medicines; product-specific dose, interactions, contraindications and monitoring must be checked at the point of care; accessed 4 August 2026.)

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.